← All trials
NCT00006286
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 1998
- Primary completion
- —
- Completion date
- Mar 1, 2004
- First posted
- —
- Last posted
- —
- Enrollment
- 432
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Mental Health (NIMH)Lead sponsor
- University of NebraskaOverall official - principal investigator
- University of OregonOverall official - principal investigator
- Johns Hopkins UniversityOverall official - principal investigator
- Northwestern UniversityOverall official - principal investigator
- Case Western Reserve UniversityOverall official - principal investigator
- University of PennsylvaniaOverall official - principal investigator
- Columbia UniversityOverall official - principal investigator
- New York UniversityOverall official - principal investigator
- Wayne State UniversityOverall official - principal investigator
- Duke UniversityStudy director
- University of North Carolina at Chapel HillOverall official - principal investigator
- University of CincinnatiOverall official - principal investigator
- The University of Texas, DallasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.